A5050768366- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Gastrointestinal Tumor Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Esophageal Cancer Research and Treatment
- Metastasis and carcinoma case studies
- Lung Cancer Treatments and Mutations
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Colorectal Cancer Surgical Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- HER2/EGFR in Cancer Research
- Neuroblastoma Research and Treatments
- Colorectal and Anal Carcinomas
- Barrier Structure and Function Studies
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
- Palliative Care and End-of-Life Issues
- Helicobacter pylori-related gastroenterology studies
- Colorectal Cancer Screening and Detection
- Esophageal and GI Pathology
- Ferroptosis and cancer prognosis
- Monoclonal and Polyclonal Antibodies Research
National Cancer Center Hospital East
2016-2025
Tokyo National Hospital
2017-2025
National Institute of Biomedical Innovation, Health and Nutrition
2022-2024
Tokyo Medical University Hospital
2024
Tokyo University of Science
2024
National Cancer Center
2019-2024
National Cancer Centre Japan
2023
Keio University
2019
Shizuoka General Hospital
2013
Abstract Objective To evaluate the efficacy and safety of tislelizumab added to chemotherapy as first line (primary) treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma compared with placebo plus chemotherapy. Design Randomised, double blind, controlled, phase 3 study. Setting 146 medical centres across Asia, Europe, North America, between 13 December 2018 28 February 2023. Participants 1657 patients aged ≥18 years human epidermal growth factor receptor 2 negative...
Recent studies have shown that immune-related adverse events (irAEs) caused by immune checkpoint inhibitors were associated with clinical benefit in patients melanoma or lung cancer. In advanced gastric cancer (AGC) patients, there been few reports about the correlation between irAEs and efficacy of inhibitors. this study, we retrospectively investigated AGC treated nivolumab.The subjects study received nivolumab monotherapy January 2015 August 2018. IrAEs defined as those AEs having a...
652 Background: There is limited evidence regarding the benefit of adding somatostatin analogs to molecular targeted agents for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This phase III trial was conducted compare everolimus plus lanreotide (EVE/LAN) with monotherapy (EVE) in patients unresectable or recurrent GEP-NETs first-line setting. Methods: Patients grade 1 2, nonfunctioning poor prognostic factors (Ki-67 labeling index (LI) 5-20% diffuse liver...
TPS510 Background: The development of immune checkpoint inhibitors (ICIs) has improved the prognosis unresectable advanced or recurrent esophageal and gastric cancer. However, remains poor. human intestinal microbiota plays various roles in digestion, immunomodulation, metabolism is known to influence tumor suppression. Previous studies reported that can impact responses effectiveness ICIs. Therefore, this study investigates safety efficacy antibiotic fecal transplantation (A-FMT) patients...
Patients with advanced gastric cancer (AGC) have poor survival after first-line treatment containing an anti-programmed death-1/ligand 1 (PD-1/PD-L1) antibody. Accumulating evidence suggests rationales for continuing immunotherapy beyond progression, synergistic effects between immune checkpoint inhibitors and angiogenesis inhibitors, a preferable combination of steroid-free chemotherapy immunotherapy. These imply that nanoparticle albumin-bound (nab)-paclitaxel plus ramucirumab in nivolumab...
Nivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers. This study reviewed the HPD patients with AGC treated nivolumab or irinotecan.The subjects this retrospective were measurable lesions, and their rates (TGR) irinotecan compared those prior therapy. was defined as increase TGR more than twofold.34 66 received third later line between June...
Abstract Background Nivolumab was approved for the treatment of advanced gastric cancer in 2017 Japan. The aim this study to assess impact nivolumab a real‐world clinical setting. Methods This single‐institutional retrospective included patients with or esophagogastric junction adenocarcinoma and history first‐line chemotherapy platinum‐based doublet triplet regimens between 2010 2020. To on survival, were divided based year approval into pre‐2017 (2010–2016) group post‐2017 (2017–2020)...
Rationale: Cancer phosphoproteomics can provide insights regarding kinases that be targeted for therapeutic applications.Monitoring the in cancer is expected to play a key role optimizing treatments with kinase inhibitors.Clinical surgical tissues and patient-derived models has been studied intensively.However, reported data may not accurately reflect phosphosignaling status patients due effect of ischemia occurring during surgery or changes characteristics cells when establishing models.In...
As circulating tumor DNA (ctDNA) measurement becomes more widespread, the "NeoRAS" phenomenon, where tissue rat sarcoma viral oncogene homolog (RAS) status converts from mutant (MT) to wild-type (WT) after treatment in metastatic colorectal cancer (mCRC), is gaining attention because ineffective epidermal growth factor receptor (EGFR) inhibitors may made effective. This study investigated its incidence and clinicopathological characteristics.In total, 107 mCRC patients (refractory or...
Small bowel adenocarcinoma (SBA) is a rare malignancy with few established chemotherapy options and dismal prognosis. We investigated the expression of claudin 18.2, nectin-4, human epidermal growth factor receptor 3 (HER3), programmed death-ligand 1 (PD-L1) in SBA to identify potential antibody drug targets analyzed associated clinicopathological features
69 Background: Appendiceal adenocarcinoma (AA), a rare cancer, has been reported to have high incidences of mucinous type histology, peritoneal metastasis, and relatively good prognosis. However, its chemotherapeutic efficacy prognostic factors is not well known. Methods: We collected patients with metastatic AA treated chemotherapy between February 2005 March 2023 in two volume cancer centers Japan. retrospectively analyzed the clinical outcomes associated treatment prognosis by...
468 Background: This study aimed to elucidate the molecular characteristics, focusing on co-amplification of ERBB2 and other oncogenes, investigate their impact treatment efficacy in HER2 positive GC. Methods: We conducted a phase 2 clinical trial (UMIN 00017602) evaluating S-1, oxaliplatin, Tmab. Next-generation sequencing was performed using TS-170 (Illumina). Results: 32 patients were enrolled, whom 6 (19%) IHC2+/FISH+. The median progression-free survival (PFS) overall (OS) 11.8 28.8...
815 Background: Cancer cachexia is a catabolic syndrome that causes weight loss and of appetite in cancer patients. Anamorelin (ANAM) an oral drug approved Japan to treat by selectively activating ghrelin receptors. There limited real-world data available on the efficacy ANAM for patients with gastrointestinal cancer. We assessed its identified associated clinical features. Methods: retrospectively collected from medical records questionnaires gastric colorectal who received between April...
796 Background: Small bowel adenocarcinoma (SBA) is an aggressive rare cancer with its incidence on the rise. Although early-onset SBA (EO-SBA: diagnosed at < 50 years old) accounts for approximately 10% of all SBA, characteristics and survival outcomes advanced EO-SBA remains under-evaluated. This study aims to evaluate clinical features treatment patients receiving first-line chemotherapy. Methods: We retrospectively analyzed data who received fluoropyrimidine plus oxaliplatin as...
352 Background: Taxane-based chemotherapy remains the standard second-line treatment after first-line including anti-PD-1 antibody therapy for patients with advanced gastric or esophagogastric junction adenocarcinoma (GA/EGA). The CheckMate 649 trial suggested that prior use of nivolumab in setting was associated longer progression-free survival (PFS) subsequent treatment. However, there have been few reports on difference efficacy taxane-based as without real-world setting. Methods: We...
799 Background: Small bowel adenocarcinoma (SBA) is a rare cancer with limited chemotherapy options. To explore TROP2 as potential therapeutic target for SBA and develop new treatment strategies, we examined protein expression in analyzed associated clinicopathological features prognosis, including PD-L1 levels the same tumor samples from our previous studies. Methods: We retrospectively reviewed patients diagnosed who underwent adjuvant or palliative between July 2010 2023 at hospital....
152 Background: MSI-high (MSI-H)/deficient MMR (dMMR) metastatic colorectal cancer (mCRC) have reported to be resistant various cytotoxic agents including fluorouracil. On the other hand, preclinical study showed that trifluridine was effective fluorouracil-refractory dMMR CRC cell lines. Previous studies on trifluridine/tipiracil (FTD/TPI) ± bevacizumab (BEV) for mCRC as later line treatment an objective response rate (ORR) of 1.1-5.6% and disease control (DCR) 44-76.6%. However, there are...
116 Background: Fluoropyrimidine agents are the key component of adjuvant chemotherapy for pathological stage III colorectal cancer (CRC). Western studies have shown that female sex is associated with favorable survival outcomes after surgery, yet a risk factor fluoropyrimidine-related adverse events (AEs) during chemotherapy. However, it remains unclear whether there differences in treatment this setting among Japanese population. Methods: Patients enrolled four randomized controlled trials...
Tislelizumab plus investigator-chosen chemotherapy (ICC) demonstrated a statistically significant improvement in overall survival (OS) versus placebo ICC RATIONALE-305 patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric cancer/gastroesophageal junction cancer (GC/GEJC) the intent-to-treat population and programmed death-ligand 1 (PD-L1) Tumor Area Positivity (TAP) score ≥ 5%. The United States Food Drug Administration...